P. Rastogi

发表

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

Gideon Blumenthal, Nina Ditsch, David Cameron, 2014, The Lancet.

Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27.

S. Paik, C. Geyer, N. Wolmark, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Association of Polymorphisms in FCGR2A and FCGR3A With Degree of Trastuzumab Benefit in the Adjuvant Treatment of ERBB2/HER2–Positive Breast Cancer: Analysis of the NSABP B-31 Trial

S. Paik, J. Costantino, C. Geyer, 2017, JAMA oncology.

Abstract S3-02: NSABP B-36: A randomized phase III trial comparing six cycles of 5-fluorouracil (5-FU), epirubicin, and cyclophosphamide (FEC) to four cycles of adriamycin and cyclophosphamide (AC) in patients (pts) with node-negative breast cancer

T. Julian, C. Geyer, D. Wickerham, 2015 .

Early and Locally Advanced Metaplastic Breast Cancer: Presentation and Survival by Receptor Status in Surveillance, Epidemiology, and End Results (SEER) 2010-2014.

L. Miller, C. Geyer, M. Schroeder, 2018, The oncologist.

Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial.

S. Paik, G. Tang, J. Costantino, 2015, The Lancet. Oncology.

Concurrent bevacizumab with a sequential regimen of doxorubicin and cyclophosphamide followed by docetaxel and capecitabine as neoadjuvant therapy for HER2- locally advanced breast cancer: a phase II trial of the NSABP Foundation Research Group.

M. Buyse, C. Geyer, N. Wolmark, 2011, Clinical breast cancer.

National Cancer Institute Breast Cancer Steering Committee Working Group Report on Meaningful and Appropriate End Points for Clinical Trials in Metastatic Breast Cancer.

L. Rubinstein, W. Barlow, M. Regan, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Poor Prognosis After Second Locoregional Recurrences in the CALOR Trial

R. Gelber, C. Geyer, N. Wolmark, 2017, Annals of Surgical Oncology.

Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE)

P. Neven, M. Okada, N. Harbeck, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract PD2-1: The effect on overall and disease-free survival (OS & DFS) by adding bevacizumab and/or antimetabolites to standard neoadjuvant chemotherapy: NSABP Protocol B-40

S. Paik, G. Tang, J. Costantino, 2015 .

NSABP B-47: A randomized phase III trial of adjuvant therapy comparing chemotherapy alone to chemotherapy plus trastuzumab in women with node-positive or high-risk node-negative HER2-low invasive breast cancer.

S. Paik, J. Costantino, C. Geyer, 2013 .

Cancer Antigen 15-3/Mucin 1 Levels in CCTG MA.32: A Breast Cancer Randomized Trial of Metformin vs Placebo

Bingshu E. Chen, T. Whelan, K. Gelmon, 2021, JNCI cancer spectrum.

The effect of metformin vs placebo on sex hormones in CCTG MA.32.

Bingshu E. Chen, T. Whelan, K. Gelmon, 2020, Journal of the National Cancer Institute.

Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial.

S. Paik, G. Tang, J. Costantino, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The impact of an aromatase inhibitor on body composition and gonadal hormone levels in women with breast cancer

S. Greenspan, V. Vogel, A. Brufsky, 2010, Breast Cancer Research and Treatment.

Trastuzumab Emtansine for Residual Invasive HER2‐Positive Breast Cancer

P. Fasching, A. Schneeweiss, Chiun-Sheng Huang, 2019, The New England journal of medicine.

Abstract S3-06: A phase III trial evaluating pCR in patients with HR+, HER2-positive breast cancer treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab (TCHP) +/- estrogen deprivation: NRG Oncology/NSABP B-52

S. Paik, N. Wolmark, S. Swain, 2017 .

OlympiA: A randomized phase III trial of olaparib as adjuvant therapy in patients with high-risk HER2-negative breast cancer (BC) and a germline BRCA1/2 mutation (gBRCAm).

R. Gelber, A. Tutt, J. Garber, 2015 .

Weekly paclitaxel and concurrent pazopanib following doxorubicin and cyclophosphamide as neoadjuvant therapy for HER-negative locally advanced breast cancer: NSABP Foundation FB-6, a phase II study

T. Julian, C. Geyer, N. Wolmark, 2014, Breast Cancer Research and Treatment.

Abstract GS1-10: Phase III study of trastuzumab emtansine (T-DM1) vs trastuzumab as adjuvant therapy in patients with HER2-positive early breast cancer with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy including trastuzumab: Primary results from KATHERINE

A. Schneeweiss, S. Loibl, M. Untch, 2019, General Session Abstracts.

Five year update of cardiac dysfunction on NSABP B-31, a randomized trial of sequential doxorubicin/cyclophosphamide (AC)->paclitaxel (T) vs. AC->T with trastuzumab (H)

J. Costantino, N. Wolmark, S. Swain, 2006 .

Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.

R. Gelber, M. Piccart, S. Lakhani, 2021, The New England journal of medicine.

Patient‐reported outcomes from KATHERINE: A phase 3 study of adjuvant trastuzumab emtansine versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for human epidermal growth factor receptor 2–positive breast cancer

A. Schneeweiss, Chiun-Sheng Huang, C. Geyer, 2020, Cancer.

Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.

W. Symmans, H. Rugo, C. Geyer, 2018, The Lancet. Oncology.

Meta-analysis Results from the Collaborative Trials in Neoadjuvant Breast Cancer (CTNeoBC)

P. Fasching, C. Perou, J. Bergh, 2012 .

The Effect of Metformin vs Placebo on Sex Hormones in Canadian Cancer Trials Group MA.32.

Bingshu E. Chen, T. Whelan, K. Gelmon, 2021, Journal of the National Cancer Institute.

Incidence of febrile neutropenia with docetaxel plus cyclophosphamide in a university-based breast oncology clinic.

V. Vogel, A. Brufsky, P. Rastogi, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Immunophenotype and proliferation to predict for response to neoadjuvant chemotherapy in TNBC: Results from BrighTNess phase III study.

C. Denkert, M. Watson, W. Symmans, 2019, Journal of Clinical Oncology.

OlympiA: A phase III, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients with germline BRCA1/2 mutations and high-risk HER2-negative early breast cancer.

R. Gelber, A. Tutt, S. Lakhani, 2021 .

Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trial.

S. Paik, J. Costantino, C. Geyer, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2.

S. Paik, J. Costantino, C. Geyer, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effect of metformin vs placebo on and metabolic factors in NCIC CTG MA.32.

Bingshu E. Chen, T. Whelan, K. Gelmon, 2015, Journal of the National Cancer Institute.

Effect of metformin versus placebo on metabolic factors in the MA.32 randomized breast cancer trial

Bingshu E. Chen, T. Whelan, K. Gelmon, 2021, NPJ breast cancer.

Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer.

E. Perez, J. Costantino, C. Geyer, 2010, The New England journal of medicine.

Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial.

S. Paik, G. Tang, J. Costantino, 2013, The Lancet. Oncology.

The Effect on Surgical Complications of Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer: NRG Oncology/NSABP Protocol B-40

S. Paik, G. Tang, J. Costantino, 2017, Annals of Surgical Oncology.

Assessment of effect size and power for survival analysis through a binary surrogate endpoint in clinical trials

S. Anderson, P. Rastogi, G. Tang, 2018, Statistics in Medicine.

Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial.

R. Gelber, C. Geyer, N. Wolmark, 2014, The Lancet. Oncology.

Phase 3 study evaluating efficacy and safety of veliparib (V) plus carboplatin (Cb) or Cb in combination with standard neoadjuvant chemotherapy (NAC) in patients (pts) with early stage triple-negative breast cancer (TNBC).

W. Symmans, H. Rugo, C. Geyer, 2017 .

Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831.

Jong-Hyeon Jeong, Norman Wolmark, Priya Rastogi, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The effect on pCR of bevacizumab and/or antimetabolites added to standard neoadjuvant chemotherapy: NSABP protocol B-40.

G. Tang, J. Costantino, C. Geyer, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bevacizumab added to neoadjuvant chemotherapy for breast cancer.

James A Young, Norman Wolmark, Rita S Mehta, 2012, The New England journal of medicine.

Efficacy of Adjuvant Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer and Tumors ≤ 2 cm: A Meta-Analysis of the Randomized Trastuzumab Trials.

E. Perez, R. Gelber, J. Costantino, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Memory impairments with adjuvant anastrozole versus tamoxifen in women with early-stage breast cancer

S. Sereika, S. Berga, C. Ryan, 2007, Menopause.

Efficacy of Chemotherapy for ER-Negative and ER-Positive Isolated Locoregional Recurrence of Breast Cancer: Final Analysis of the CALOR Trial.

R. Gelber, C. Geyer, N. Wolmark, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract 2837: A surrogate gene expression signature of tumor infiltrating lymphocytes (TILs) predicts degree of benefit from trastuzumab added to standard adjuvant chemotherapy in NSABP (NRG) trial B-31 for HER2+ breast cancer

J. Costantino, C. Geyer, D. Wickerham, 2015 .

A pooled analysis of the cardiac events in the trastuzumab adjuvant trials

R. Gelber, D. Zardavas, M. Piccart-Gebhart, 2019, Breast Cancer Research and Treatment.

Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31.

Jong-Hyeon Jeong, Hanna Bandos, Debora Fumagalli, 2013, Journal of the National Cancer Institute.

What do perceived cognitive problems reflect?

Susan M. Richey, Priya Rastogi, S. Sereika, 2008, The journal of supportive oncology.

Abstract S1-11: Meta-analysis Results from the Collaborative Trials in Neoadjuvant Breast Cancer (CTNeoBC)

P. Fasching, C. Perou, J. Bergh, 2012 .

Germline genome-wide association studies in women receiving neoadjuvant chemotherapy with or without bevacizumab

Krishna R. Kalari, Erin E. Carlson, P. Fasching, 2018, Pharmacogenetics and genomics.

Abstract PD2-01: High Ki-67 as a biomarker for identifying patients with high risk early breast cancer treated in monarchE

P. Fasching, N. Harbeck, S. Johnston, 2021 .

Patient-reported outcomes (PROs) from KATHERINE: A phase III study of adjuvant trastuzumab emtansine (T-DM1) versus trastuzumab (H) in patients (pts) with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer.

A. Schneeweiss, Chiun-Sheng Huang, C. Geyer, 2019, Journal of Clinical Oncology.

216TiPOlympiA: A randomized phase III trial of olaparib as adjuvant therapy in patients with high-risk HER2-negative breast cancer (BC) and a germline BRCA1/2 mutation (gBRCAm)

R. Gelber, A. Tutt, J. Garber, 2017 .

Risedronate may preserve bone microarchitecture in breast cancer survivors on aromatase inhibitors: A randomized, controlled clinical trial.

S. Greenspan, A. Brufsky, B. Lembersky, 2016, Bone.

Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents

Bingshu E. Chen, T. Whelan, K. Gelmon, 2011, Breast Cancer Research and Treatment.

Body Mass Index at Diagnosis and Breast Cancer Survival Prognosis in Clinical Trial Populations from NRG Oncology/NSABP B-30, B-31, B-34, and B-38

G. Tang, J. Costantino, C. Geyer, 2015, Cancer Epidemiology, Biomarkers & Prevention.

NSABP B-41, a Randomized Neoadjuvant Trial: Genes and Signatures Associated with Pathologic Complete Response

G. Tang, C. Geyer, N. Wolmark, 2020, Clinical Cancer Research.

21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer

S. Paik, G. Tang, S. Shak, 2018, npj Breast Cancer.

Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31.

Greg Yothers, Michael Ewer, Norman Wolmark, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

An exploratory study of host polymorphisms in genes that clinically characterize breast cancer tumors and pretreatment cognitive performance in breast cancer survivors.

Theresa A. Koleck, S. Sereika, Y. Conley, 2017, Breast cancer.

Targeting alternative pathways in HER2-positive breast cancer.

P. Rastogi, 2010, Oncology.

Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer

C. Geyer, N. Wolmark, S. Swain, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

CA15-3/MUC1 in CCTG MA-32 (NCT01101438): A phase III RCT of the effect of metformin vs. placebo on invasive disease free and overall survival in early stage breast cancer (BC).

Bingshu E. Chen, T. Whelan, K. Gelmon, 2018 .

NSABP B-59/GBG 96-GeparDouze: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy (NAC) with atezolizumab or placebo in Patients (pts) with triple negative breast cancer (TNBC) followed by adjuvant atezolizumab or placebo.

C. Denkert, J. Costantino, C. Geyer, 2018 .

Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial.

S. Paik, C. Geyer, D. Wickerham, 2019, The Lancet. Oncology.

Identifying Principal Stratum Causal Effects Conditional on a Post-treatment Intermediate Response

G. Tang, P. Rastogi, Xiaoqing Tan, 2021, CLEaR.

A phase II neoadjuvant trial of sequential nanoparticle albumin-bound paclitaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide in locally advanced breast cancer.

A. Buzdar, C. Geyer, N. Wolmark, 2010, Clinical breast cancer.

The attitudes, communication, treatment, and support intervention to reduce breast cancer treatment disparity.

M. Rosenzweig, A. Brufsky, P. Rastogi, 2011, Oncology nursing forum.

Gemcitabine/epirubicin/paclitaxel as neoadjuvant chemotherapy in locally advanced breast cancer: a phase II trial of the NSABP Foundation Research Group.

G. Tseng, S. Paik, W. Kim, 2008, Clinical breast cancer.

Stromal Tumor-infiltrating Lymphocytes in NRG Oncology/NSABP B-31 Adjuvant Trial for Early-stage HER2-positive Breast Cancer.

S. Paik, J. Costantino, C. Geyer, 2019, Journal of the National Cancer Institute.

Pathologic complete response and outcomes by intrinsic subtypes in NSABP B-41, a randomized neoadjuvant trial of chemotherapy with trastuzumab, lapatinib, or the combination

G. Tang, C. Geyer, N. Wolmark, 2019, Breast Cancer Research and Treatment.

Evaluation of lapatinib as a component of neoadjuvant therapy for HER2+ operable breast cancer: 5-year outcomes of NSABP protocol B-41.

S. Paik, G. Tang, J. Costantino, 2016 .

Abstract OT3-05-05: MonarchE: A randomized, open-label, phase 3 study of abemaciclib combined with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone in patients with high risk, node positive, early stage, HR+, HER2- breast cancer

N. Harbeck, S. Johnston, M. Toi, 2018 .

Intrinsic subtypes of HER2-positive breast cancer and their associations with pathologic complete response (pCR) and outcomes: Findings from NSABP B-41, a randomized neoadjuvant trial.

G. Tang, C. Geyer, N. Wolmark, 2018 .

Update on breast cancer prevention.

V. Vogel, P. Rastogi, 2003, Oncology.

Chemoprevention in postmenopausal women

P. Rastogi, 2008, Menopause.

Trastuzumab as Single Agent Therapy for HER2-Positive Metastatic Breast Cancer

N. Davidson, P. Rastogi, 2010, Oncology Research and Treatment.

Chemotherapy (CT) for isolated locoregional recurrence (ILRR) of breast cancer in ER-positive (ER+) and ER-negative (ER-) cohorts: Final analysis of the CALOR trial.

R. Gelber, N. Wolmark, J. Nortier, 2017 .

Prevention of bone loss with risedronate in breast cancer survivors: a randomized, controlled clinical trial

S. Greenspan, A. Brufsky, B. Lembersky, 2015, Osteoporosis International.

Polymorphisms in DNA repair and oxidative stress genes associated with pre-treatment cognitive function in breast cancer survivors: an exploratory study

Theresa A. Koleck, S. Sereika, Y. Conley, 2016, SpringerPlus.

NRG Oncology/NSABP B-47 menstrual history study: impact of adjuvant chemotherapy with and without trastuzumab

C. Geyer, N. Wolmark, P. Ganz, 2021, NPJ breast cancer.

Milestone clinical trials of the National Surgical Adjuvant Breast and Bowel Project (NSABP).

T. Julian, C. Geyer, D. Wickerham, 2017, Chinese clinical oncology.

Association of Immunophenotype With Pathologic Complete Response to Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: A Secondary Analysis of the BrighTNess Phase 3 Randomized Clinical Trial.

C. Denkert, M. Watson, W. Symmans, 2021, JAMA oncology.

Evaluation of lapatinib as a component of neoadjuvant therapy for HER2+ operable breast cancer: NSABP protocol B-41.

S. Paik, G. Tang, J. Costantino, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract OT1-03-11: Phase III randomized, placebo-controlled clinical trial evaluating the use of adjuvant endocrine therapy +/- one year of everolimus in patients with high-risk, hormone receptor (HR) positive and HER2-negative breast cancer (BC): SWOG/NRG/Alliance S1207 (NCT01674140)

L. Pusztai, S. Paik, W. Barlow, 2015 .

HER2 targeting in early breast cancer: more options and more questions.

B. Lembersky, P. Rastogi, 2014, Oncology.

Breast Cancer -targets and Therapy Dovepress an Exploratory Study of Host Polymorphisms in Genes That Clinically Characterize Breast Cancer Tumors and Pretreatment Cognitive Performance in Breast Cancer Survivors

Theresa A. Koleck, S. Sereika, Y. Conley, 2022 .

Effect of metformin versus placebo on weight and metabolic factors in initial patients enrolled onto NCIC CTG MA.32, a multicenter adjuvant randomized controlled trial in early-stage breast cancer (BC).

Bingshu E. Chen, T. Whelan, K. Gelmon, 2013 .

Locoregional recurrence (LRR) after neoadjuvant chemotherapy (NAC): Pooled-analysis results from the Collaborative Trials in Neoadjuvant Breast Cancer (CTNeoBC).

J. Costantino, C. Geyer, N. Wolmark, 2014, Journal of Clinical Oncology.

215TiPPALLAS: PALbociclib CoLlaborative adjuvant study: A randomized phase 3 trial of palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for HR+/HER2- early breast cancer

M. Piccart, M. Gnant, A. DeMichele, 2017 .

21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer

S. Paik, G. Tang, S. Shak, 2018, npj Breast Cancer.

Update of cardiac dysfunction on NSABP B-31, a randomized trial of sequential doxorubicin/cyclophosphamide (AC)→paclitaxel (T) vs. AC→T with trastuzumab (H).

N. Wolmark, S. Swain, E. Romond, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Validation of the NSABP/NRG Oncology 8-Gene Trastuzumab-benefit Signature in Alliance/NCCTG N9831

D. Serie, E. Thompson, S. Paik, 2020, JNCI cancer spectrum.

A phase II neoadjuvant trial of sequential nanoparticle albumin-bound paclitaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide in locally advanced breast cancer.

A. Buzdar, C. Geyer, N. Wolmark, 2010, Clinical breast cancer.

Effects of metformin versus placebo on vitamin B12 metabolism in non-diabetic breast cancer patients in CCTG MA.32

Bingshu E. Chen, T. Whelan, K. Gelmon, 2017, Breast Cancer Research and Treatment.

Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer.

E. Perez, J. Costantino, C. Geyer, 2010, The New England journal of medicine.

Abstract S5-5: Trastuzumab plus adjuvant chemotherapy for HER2-positive breast cancer: Final planned joint analysis of overall survival (OS) from NSABP B-31 and NCCTG N9831

E. Winer, S. Martino, G. Sledge, 2012 .

NSABP FB-6: Phase II trial of weekly paclitaxel (WP) and pazopanib following doxorubicin and cyclophosphamide (AC) as neoadjuvant therapy for HER2-negative locally advanced breast cancer (LABC).

M. Buyse, T. Julian, S. Paik, 2012 .

Abstract OT-03-01: Trastuzumab deruxtecan (T-DXd; DS-8201) vs trastuzumab emtansine (T-DM1) in high-risk patients with HER2-positive, residual invasive early breast cancer after neoadjuvant therapy: A randomized, phase 3 trial (DESTINY-Breast05)

C. Geyer, S. Loibl, M. Untch, 2021 .